| 000 | 01826naaaa2200301uu 4500 | ||
|---|---|---|---|
| 001 | https://directory.doabooks.org/handle/20.500.12854/53831 | ||
| 005 | 20220219195625.0 | ||
| 020 | _aintechopen.69830 | ||
| 020 | _a9781789233544 | ||
| 020 | _a9781789233551 | ||
| 024 | 7 |
_a10.5772/intechopen.69830 _cdoi |
|
| 041 | 0 | _aEnglish | |
| 042 | _adc | ||
| 100 | 1 |
_aDimitrios P. Vlachakis _4auth |
|
| 245 | 1 | 0 | _aMolecular Docking |
| 260 |
_bIntechOpen _c2018 |
||
| 300 | _a1 electronic resource (188 p.) | ||
| 506 | 0 |
_aOpen Access _2star _fUnrestricted online access |
|
| 520 | _aMolecular docking has always been and will be on the forefront of developments in the eminent field of drug design and medicinal chemistry. At the early days, drug discovery was based on blackboard drawings and expert intuition. However, as times move on, the amount of available information and overall knowledge base that needs to be analyzed cannot be processed manually. This, coupled by the rapid growth in computational infrastructure and processing power, has allowed for the efficient use of molecular docking tools and algorithms to be considered in the greater field of drug discovery. In the postgenomic era, molecular docking has become the key player for the screening of hundreds of thousands of compounds against a repertoire of pharmacological targets. | ||
| 540 |
_aAll rights reserved _4http://oapen.org/content/about-rights |
||
| 546 | _aEnglish | ||
| 653 | _aLife Sciences | ||
| 653 | _aMolecular Biology | ||
| 653 | _aGenetics and Molecular Biology | ||
| 653 | _aBiochemistry | ||
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://www.intechopen.com/books/molecular-docking _70 _zDOAB: download the publication |
| 856 | 4 | 0 |
_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/53831 _70 _zDOAB: description of the publication |
| 999 |
_c40100 _d40100 |
||